Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs United Parcel Service Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while United Parcel Service Inc trades at $95.6 (market cap $80.65B). The key difference: United Parcel Service Inc is far larger — about 10.7× Spyre Therapeutics Inc. Common Stock's market cap, and United Parcel Service Inc pays a 6.92% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and United Parcel Service Inc for 141 Days on average.
| SYRE | UPS | |
|---|---|---|
Market Cap | $7.52B | $80.65B |
Volume | 1,441,031 | 3,099,263 |
Sector | Health | Industrials |
52-Week High | $108.92 | $120.00 |
52-Week Low | $22.18 | $84.09 |
Typical Hold Time | 0 Days | 141 Days |
Enterprise Value | $6.52B | $104.67B |
Dividend Yield | — | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
UPS trades at $94.76, down 0.61% on the day, with a bullish technical signal despite recent pressure from fuel costs and transport sector headwinds. The company has beaten earnings estimates for three consecutive quarters, maintaining a 5.08% net margin and 29.66% ROE. Recent developments include the launch of UPS Secure Commerce and an exclusive TikTok Shop returns partnership, positioning the company for e-commerce growth.
UPS offers value with a 17.62 P/E ratio and 7% dividend yield, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Analyst consensus is mixed with a $118.67 price target representing 25% upside, but competitive pressures and margin compression remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
